Todd P. Branning - 03 Nov 2022 Form 4 Insider Report for NeuBase Therapeutics, Inc. (NBSE)

Role: Chief Financial Officer
Signature: /s/ Todd P. Branning
Issuer symbol: NBSE
Transactions as of: 03 Nov 2022
Net transactions value: $0
Form type: 4
Filing time: 04 Nov 2022, 17:00:34 UTC
Previous filing: 21 Mar 2022
Next filing: 17 Mar 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NBSE	Stock option (right to buy)	Award	$0	+200,000		$0.000000	200,000	03 Nov 2022	Common Stock	200,000	$0.2800	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	50% of the total shares shall vest on March 1, 2023, and the remaining shares shall vest on November 1, 2023, provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date, inclusive. Shares are subject to accelerated vesting in the event of a change of control of the Issuer, provided that employment has not terminated prior to such vesting date, inclusive.

Content

50% of the total shares shall vest on March 1, 2023, and the remaining shares shall vest on November 1, 2023, provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date, inclusive. Shares are subject to accelerated vesting in the event of a change of control of the Issuer, provided that employment has not terminated prior to such vesting date, inclusive.